Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Geron to present real-world claims study of imetelstat in lower-risk MDS at Japan hematology meeting

Geron to present real-world claims study of imetelstat in lower-risk MDS at Japan hematology meeting

BitgetBitget2026/10/12 12:05
  • Geron flagged new real-world and clinical analyses of imetelstat in lower-risk myelodysplastic syndromes for upcoming presentations in Japan and Europe.
  • Data from US claims are set to show most patients stayed on therapy through early treatment months despite heavy comorbidity.
  • Separate IMerge-derived analyses are expected to indicate durable responses in some patients, with early, generally manageable blood-count suppression.
  • Another presentation will outline evidence that telomerase inhibition may affect disease biology, supporting imetelstat’s positioning beyond symptomatic benefit.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120803PRIMZONEFULLFEED9843834) on October 12, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Masayoshi Son's Trillion-Dollar Gamble: Once Considered Acquiring SK Hynix

According to reports, Masayoshi Son once planned to acquire the South Korean memory chip giant SK Hynix for nearly 1 trillion US dollars and had approached Wall Street institutions to seek financing, but SoftBank has confirmed it is no longer actively pursuing the deal. The massive financing requirement and South Korean regulatory restrictions were major obstacles. This plan also highlights SoftBank’s further strategic intention to invest in AI storage chips.

华尔街见闻•2026/11/21 03:16

"Sell-offs bring more sell-offs! Goldman Sachs predicts another large-scale sell-off in the U.S. stock market in the coming week."

Goldman Sachs stated that the bank’s “panic index” has risen to 9 out of 10, with systemic selling pressure continuing to spread. In the coming week, CTAs may sell up to $80.6 billion in US stocks, and even if the market remains flat, there is still $65.8 billion in sell orders waiting to be executed. The Anthropic IPO failed to boost market risk appetite, and concerns over AI investment returns continue to weigh on tech stock valuations.

华尔街见闻•2026/11/21 02:16